Fonte: The Journal of Clinical Pharmacology. Unidades: FCFRP, FMRP
Assuntos: FÁRMACOS, HIPERTENSÃO, FARMACOCINÉTICA, ANTIDEPRESSIVOS
ABNT
TOZATTO, Eduardo et al. Nifedipine does not alter the pharmacokinetics of venlafaxine enantiomers in healthy subjects phenotyped for CYP2D6, CYP2C19, and CYP3A. The Journal of Clinical Pharmacology, v. 61, n. 3, p. 319-327, 2021Tradução . . Disponível em: https://doi.org/10.1002/jcph.1745. Acesso em: 10 set. 2024.APA
Tozatto, E., Benzi, J. R. de L., Rocha, A., Coelho, E. B., & Lanchote, V. L. (2021). Nifedipine does not alter the pharmacokinetics of venlafaxine enantiomers in healthy subjects phenotyped for CYP2D6, CYP2C19, and CYP3A. The Journal of Clinical Pharmacology, 61( 3), 319-327. doi:10.1002/jcph.1745NLM
Tozatto E, Benzi JR de L, Rocha A, Coelho EB, Lanchote VL. Nifedipine does not alter the pharmacokinetics of venlafaxine enantiomers in healthy subjects phenotyped for CYP2D6, CYP2C19, and CYP3A [Internet]. The Journal of Clinical Pharmacology. 2021 ; 61( 3): 319-327.[citado 2024 set. 10 ] Available from: https://doi.org/10.1002/jcph.1745Vancouver
Tozatto E, Benzi JR de L, Rocha A, Coelho EB, Lanchote VL. Nifedipine does not alter the pharmacokinetics of venlafaxine enantiomers in healthy subjects phenotyped for CYP2D6, CYP2C19, and CYP3A [Internet]. The Journal of Clinical Pharmacology. 2021 ; 61( 3): 319-327.[citado 2024 set. 10 ] Available from: https://doi.org/10.1002/jcph.1745